コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nderwent the same evaluations over 6 months (observation group).
2 idation and maintenance group and 103 in the observation group).
3 ion (medication group) or close observation (observation group).
4 ervention group) or conservative management (observation group).
5 (experimental group) or without olanzapine (observation group).
6 maintenance group and 603 in the placebo or observation group).
7 e (three from the SRS group and one from the observation group).
8 ) or nodal observation with ultrasonography (observation group).
9 usions (transfusion group) or standard care (observation group).
10 Thirty-two patients served as controls (observation group).
11 ease (61 in the vitespen group and 63 in the observation group).
12 parameters deteriorated significantly in the observation group.
13 had longer 5- and 10-year survival than the observation group.
14 Neither response predicted survival in the observation group.
15 rum GH response 28.2 mU/L [6.8]) acted as an observation group.
16 ne group and 22 (10%) of 224 patients in the observation group.
17 d 2.0 months (95% CI, 1.8-2.7 months) in the observation group.
18 ned to the capecitabine group and 224 to the observation group.
19 zolizumab group and 403 were assigned to the observation group.
20 apy and olanzapine and by no patients in the observation group.
21 ab group and in 31.6% of the patients in the observation group.
22 olumab and seven [11%] of 61 patients in the observation group.
23 9.7 months (95% CI, 13.3-24.4 months) in the observation group.
24 pared with seven (7%) of 103 patients in the observation group.
25 .7 ng/mL; P < .001) but was unchanged in the observation group.
26 reported for the OHTS calculator in the OHTS observation group.
27 consolidation and maintenance group and the observation group.
28 d 5.6% ([4 of 72] 95% CI, 1.5%-13.6%) in the observation group.
29 oxygen uptake efficiency slope than did the observation group.
30 tions in both the lenalidomide group and the observation group.
31 ine group and 17.4 months (12.0-23.7) in the observation group.
32 ine group and 17.5 months (12.0-23.8) in the observation group.
33 dissection group and in 6.3% of those in the observation group.
34 ned to the capecitabine group and 224 to the observation group.
35 ars (with the same dose schedule), or to the observation group.
36 year trastuzumab group, and 15 (0.9%) in the observation group.
37 ation alone, and 87 patients enrolled in the observation group.
38 ab group, and 36 (5%) of 672 patients in the observation group.
39 because of melanoma versus 139 (95%) in the observation group.
40 group, and 146 (22%) of 672 patients in the observation group.
41 vacizumab group and 25 months (17-37) in the observation group.
42 halidomide-prednisone and 34.1 months in the observation group.
43 with thalidomide-prednisone versus 6 in the observation group.
44 atients in the vitespen group and 367 in the observation group.
45 vs -0.49 +/- 0.48 (P = .242) in the PPV and observation groups.
46 s vs 3.49 +/- 4.43 (P = .954) in the PPV and observation groups.
47 change was observed in the blood donation or observation groups.
48 difference in tumor growth in treatment and observation groups.
49 the aflibercept, laser photocoagulation, and observation groups.
50 1% to 21%) were observed in the adjuvant and observation groups.
53 and visual gain were respectively in PPV vs observation groups: (1) small MH 0.37 +/- 0.52 vs 0.42 +
55 red forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m2 of f
56 reatment group (77 percent) and 9 men in the observation group (18 percent) were alive and had no evi
57 rved in eyes in the highest tertile, initial observation group (20-year conversion rate: 61.1% in the
60 in 10 of the 165 participants (6.1%) in the observation group (3 of these 10 started treatment witho
61 e medications significantly increased in the observation group (30 [11%]) compared with the olanzapin
62 group, 49 patients) or no further treatment (observation group, 46 patients) for the brain metastasis
63 ie of neurologic causes than patients in the observation group (6 [14%] of 43 who died vs 17 [44%] of
64 y higher in the dissection group than in the observation group (68+/-1.7% and 63+/-1.7%, respectively
65 87.2% (95% CI, 83.1% to 90.5%) in the direct-observation group, 74.0% (CI, 68.9% to 78.6%) in the sel
67 was similar in the dissection group and the observation group (86+/-1.3% and 86+/-1.2%, respectively
68 equent in the radiotherapy group than in the observation group (9 [18%] of 49 vs 32 [70%] of 46; P<.0
69 th 36.1 months (95% CI, 29.7 to 44.2) in the observation group (adjusted hazard ratio 0.84; 95% CI, 0
70 compared with 36.4 months (29.7-44.5) in the observation group (adjusted hazard ratio [HR] 0.81, 95%
71 ecitabine group and 36 months (30-44) in the observation group (adjusted HR 0.75, 95% CI 0.58-0.97; p
74 ed in the biopsy group, as compared with the observation group, among patients with intermediate-thic
75 ts was 19.5% and 13.2%, respectively, in the observation group and 13.1% and 5.8%, respectively, in t
76 Sixty-two percent (95% CI, 49-74) in the observation group and 34% (95% CI, 23-48) in the glasses
77 cal recurrence was 43% (95% CI 31-59) in the observation group and 72% (60-87) in the SRS group (haza
78 in 4.6% (4 of 87) of the participants in the observation group and in 2.2% (2 of 90) of the participa
79 erioration occurred in 2.3% (2 of 87) of the observation group and in 2.2% (2 of 90) of the patching
80 s were as follows: 15 of 152 patients in the observation group and two of 160 patients in the enoxapa
82 operative treatment of appendix mass (active observation group) and incidence of severe complications
83 e ofatumumab group vs 23 [10%] of 237 in the observation group) and infections (31 [13%] vs 20 [8%]).
84 (two in the vitespen group and seven in the observation group), and 124 patients with baseline metas
85 % CI, 44.5%-53.8%) among participants in the observation group, and 41.9% (95% CI, 37.2%-46.3%) among
86 group compared with 81.3% (74.2-86.7) in the observation group, and in high-risk patients, it was 74.
87 the lenalidomide group and 226 (27%) in the observation group, and no deaths in the lenalidomide gro
88 group compared with 63.7% (52.8-72.7) in the observation group; and in ultra-high-risk patients it wa
89 nt group and six events in the half-the-size observation group, are not mature enough to draw conclus
91 rall survival (P = .07) as compared with the observation group, but had severe treatment-related toxi
92 ree survival rate was 86.7% +/- 9.5% for the observation group, compared with 69.2% +/- 13% and 40.7%
93 0 years, regardless of treatment assignment (observation group: DFS HR age </= 40 v > 40 years, 1.18;
94 e chemotherapy group and four (0.25%) in the observation group died from non-colorectal cancer causes
95 the glasses group and 18 (34%) of 53 in the observation group (difference = -13%; 95% confidence int
96 icant differences between the olanzapine and observation groups for nausea control (264 [96%] vs 234
97 -11.86], P = .02, n = 2 studies), while the observation group had a significantly lower SRF height a
98 group and three (1%) of 237 patients in the observation group had adverse events that led to permane
99 the WBRT group and 51.4% of patients in the observation group had died (P = .28), with no difference
101 intenance group and 13 months (11-18) in the observation group (hazard ratio 0.55 [95% CI 0.39-0.78];
102 in the vitespen group and 31 (27.0%) in the observation group (hazard ratio 0.576, 95% CI 0.324-1.02
103 in the vitespen group and 146 (39.8%) in the observation group (hazard ratio 0.923, 95% CI 0.729-1.16
104 s-free estimate, 13.2 years) of those in the observation group (hazard ratio [HR], 0.75; 95% CI, 0.55
105 rred with PEG-IFN-alpha-2b versus 406 in the observation group (hazard ratio [HR], 0.87; 95% CI, 0.76
106 as higher in the rituximab group than in the observation group (hazard ratio for death, 0.50; 95% CI,
107 % in the biopsy group and 73.1+/-2.1% in the observation group (hazard ratio for recurrence[corrected
108 ide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0
109 red with 6.7 (95% CI, 6.0-7.5) months in the observation group (hazard ratio, 0.55 [95% CI, 0.44-0.69
110 hereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0
111 alidomide group and 80.2% (76.0-84.4) in the observation group (HR 0.69 [95% CI 0.52-0.93]; p=0.014),
112 bevacizumab group compared with those in the observation group (HR 0.83, 95% CI 0.70-0.98, p=0.03), b
113 alidomide group and 75.8% (72.4-79.2) in the observation group (HR 0.87 [95% CI 0.73-1.05]; p=0.15).
114 maximally tolerable doses compared with the observation group in the European Organization for Resea
116 ly longer in the treatment group than in the observation group (median not reached vs. 21 months; haz
117 nts in the capecitabine group and 220 in the observation group), median overall survival was 53 month
118 Rescue treatment was used more often in the observation group (n = 32) than in the azacitidine maint
120 , 132 patients were randomly assigned to the observation group (n=68) or SRS group (n=64), with 128 p
121 nces (73 in the vitespen group and 76 in the observation group), nine deaths before recurrence (two i
122 hs related to adverse events occurred in the observation group; no deaths were attributed to the stud
123 erapy, with median time to treatment for the observation group of 12 months (range, 4 to 128 months).
125 ion, with lymphadenectomy for nodal relapse (observation group), or wide excision and sentinel-node b
126 nd between intravitreal bevacizumab group vs observation group (P = .45) Steroid-induced cataract was
128 ETDRS letter decrease was documented in the observation group (p>0.90) and a 1.1 (p=0.14) ETDRS lett
129 s was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating disease progress
132 therapy, as compared with 58% and 71% in the observation group (P=.0006 for DFS and P=.02 for OS).
136 0 deaths in the vitespen group and 72 in the observation group (p=0.896); however, overall survival d
138 umab group vs 20 [5%] of 397 patients in the observation group), pyelonephritis (12 [3%]) vs 14 [4%])
139 more quality-of-life-adjusted time than the observation group regardless of the relative valuations
140 the aflibercept, laser photocoagulation, and observation groups, respectively (aflibercept vs laser p
147 higher in the trastuzumab group than in the observation group (severe CHF, 0.8% v 0.0%; confirmed si
148 % CI = [1.54, 11.72], P = .005), whereas the observation group showed a higher resolution rate at 12
149 were better for the SLNB group than for the observation group, specifically among patients with inte
151 ed for eyes in the laser photocoagulation or observation groups that had decreased visual acuity from
155 ths in the chemotherapy group and 370 in the observation group; the relative risk of death from any c
156 ces in the chemotherapy group and 359 in the observation group; the relative risk of recurrence with
159 ariate analysis, the survival profile of the observation group was statistically superior to that of
160 the primary end point in the transfusion and observation groups was 2.0 and 4.8 events, respectively,
161 t 12 months and 84% at 24 months, and in the observation group were 77% at 12 months and 73% at 24 mo
162 patients in the vitespen group and 42 in the observation group were excluded from the ITT population
166 to withdrawal of consent; two in the active observation group were withdrawn because they became ine
168 nt group and 127 events and 91 deaths in the observation group, with 5-year disease-free survival rat
169 study visit was similar between the MRA and observation groups (WMD=-0.01 logMAR, 95% CI = [-0.05, 0